Bolt Biotherapeutics Reports Q3 2025 Financial Results, Highlights Pipeline Progress, and Seeks Partner for Lead Candidate BDC-3042

Bolt Biotherapeutics reported a narrowed net loss of $7.1 million in Q3 2025, compared to a loss of $15.2 million in the same period last year. The company's cash position of $38.8 million is expected to fund operations and key milestones into 2027. Bolt's pipeline includes two clinical-stage candidates, BDC-3042 and BDC-4182, designed to harness the innate and adaptive immune system to combat solid tumors. BDC-3042, a first-in-class agonist antibody targeting dectin-2, is being partnered with a pharmaceutical company, while BDC-4182 is a next-generation Boltbody ISAC targeting claudin 18.2.